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Abstract
Background The long-term prognosis of immunoglobulin
A nephropathy (IgAN) is reportedly poor. In Japan,
tonsillectomy-steroid pulse therapy has frequently been
used for treatment of early IgAN, with favorable outcomes.
However, steroid usage is sometimes limited due to
adverse reactions. To reduce the total dose of steroids, we
have been using mizoribine (MZR) in combination with
tonsillectomy-steroid pulse therapy since 2004. Here we
report a retrospective evaluation of our protocol outcome.
Methods Forty-two patients aged\70 years with histop-
athologically conﬁrmed IgAN and an estimated glomerular
ﬁltration rate (eGFR) of 30 ml/min/1.73 m
2 or higher were
enrolled. After giving informed consent, all the patients
underwent bilateral tonsillectomy. One week later, intra-
venous methylprednisolone pulse therapy (500 mg/day)
was administered for 3 days, followed by oral prednisolone
(30 mg/day and tapered to 0 over 7 months) and MZR
(150 mg/day for 11 months). The complete remission (CR)
rate and renoprotective effect were assessed.
Results The CR rate at 6, 12, and 24 months was 33.3,
69.1, and 76.2%, respectively. Despite a relatively low total
steroid dose, renal function was satisfactorily maintained
for 24 months or longer with no relapse. The eGFR in
patients with stage 3 chronic kidney disease was signiﬁ-
cantly improved at 6 months after start of treatment. Three
patients (7.1%) had mild and transient adverse events.
Conclusion This protocol appears to be highly effective
and safe for IgAN patients with renal dysfunction.
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Introduction
Immunoglobulin A nephropathy (IgAN) was ﬁrst described
by Berger et al. [1]. Approximately 40% of IgAN patients
develop renal failure within 20 years of diagnosis, and the
long-term prognosis is poor [2]. Pozzi et al. [3] reported
that corticosteroid therapy for IgAN exerted a renoprotec-
tive effect, but that relapse of proteinuria was observed in a
relatively large number of patients after treatment. This
report also suggested that complete remission (CR) cannot
be achieved without preventing continuous tissue deposi-
tion of IgA.
Focal infection of the palatine tonsils or other mucosal
sites causes immune abnormalities, leading to sugar-chain
incompleteness in IgA1, which is then overproduced and
deposited in renal glomeruli [4]. In Japan, high rates of CR
have been reported in patients with early IgAN after
bilateral palatine tonsillectomy and steroid pulse therapy
[5, 6]. In some patients, however, steroid-associated
adverse events have occurred in a dose-dependent manner,
necessitating dose reduction. An increase in the number of
sclerotic glomeruli as well as in the degree of interstitial
ﬁbrosis due to steroid therapy has also been reported in
patients with low glomerular ﬁltration rates (GFRs) [7].
Mizoribine (MZR) is an immunosuppressive agent used
for the treatment of nephrotic syndrome caused by primary
glomerulonephritis. A decrease in the intensity of IgA
T. Kaneko (&)  A. Hirama  K. Ueda  T. Fujino 
K. Utsumi  Y. Iino  Y. Katayama
Divisions of Neurology, Nephrology and Rheumatology,
Department of Internal Medicine, Nippon Medical School,
1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
e-mail: tomohiro@nms.ac.jp
123
Clin Exp Nephrol (2011) 15:73–78
DOI 10.1007/s10157-010-0356-2staining in glomerular mesangial areas, as well as a
decrease in the number of B cells and IgA-bearing B cells,
has been demonstrated in a MZR-treated animal model of
IgAN [8]. In another study involving 34 children with
diffuse IgAN who received steroid pulse therapy in com-
bination with MZR, there was a signiﬁcant decrease in the
degree of IgA deposition and inﬁltration of the glomeruli
by CD68-positive cells and alpha-smooth muscle actin-
positive cells, and consequently a decrease in the extent of
tissue damage [9]. Other reports have also indicated that
MZR ameliorates glomerular sclerosis and tubulointersti-
tial ﬁbrosis [10, 11].
To reduce the total dose of steroids, since 2004 we have
been using MZR for IgAN in combination with tonsillec-
tomy and steroid pulse therapy. Speciﬁcally, patients
receive one course of steroid pulse therapy instead of the
current three courses and postoperative oral steroid therapy
for 7 months instead of 11 months, in combination with
MZR. In the present study, data from 42 patients followed
up for at least 24 months were used to determine the rate of
CR (assessed by urinalysis), the treatment efﬁcacy in pro-
tecting against renal function deterioration, and the safety
of the therapy.
Patients and methods
Patients
We retrospectively assessed the therapeutic outcome of
MZR in combination with tonsillectomy plus steroid pulse
therapy in 42 patients who fulﬁlled the following eligibility
criteria and were followed up for at least 2 years: (1) IgAN
diagnosed by renal biopsy, with grade 2, 3, or 4 histologic
lesions [12]; (2) persistent microscopic hematuria and
proteinuria; (3) a serum creatinine level of \2.0 mg/dl;
(4) an estimated glomerular ﬁltration rate (eGFR) of
30 ml/min/1.73 m
2 or higher; (5) age \70 years; and (6)
willingness to provide written informed consent.
We excluded patients for whom steroids were contra-
indicated and also those in whom the renal disease was
associated with systemic lupus erythematosus or other
systemic diseases. Patients whose urinary protein/
creatinine ratio was less than 0.1 (g/g) were also excluded
from the study.
Therapeutic intervention
After obtaining informed consent, bilateral palatine ton-
sillectomy was performed on all patients. One week after
surgery, intravenous methylprednisolone (mPSL) pulse
therapy (500 mg/day) was administered for 3 days, and
each patient was started on an antiplatelet drug (dilazep
hydrochloride or dipyridamole), an anti-ulcer drug, and
sulfamethoxazole-trimethoprim (SMX–TMP). After the
mPSL pulse therapy, the patients continued to receive oral
prednisolone (PSL) at a dose of 30 mg per day for 4 weeks,
and then once every 2 days thereafter in combination with
MZR at 150 mg/day once daily. The dose of PSL was then
decreased by 5 mg every 4 weeks and discontinued in the
7th month. SMX-TMP and the anti-ulcer drug were dis-
continued, in principle, when the PSL dose was 20 mg
administered every 2 days. MZR and the antiplatelet drug
were continued for 11 months (Fig. 1). Patients with
hypertension received an antihypertensive drug such as a
renin-angiotensin system inhibitor.
Efﬁcacy assessment
The primary endpoint was the rate of CR (assessed by
urinalysis at 6, 12, and 24 months for proteinuria and
hematuria). CR was deﬁned as remission of both protein-
uria and hematuria, speciﬁcally, (1) a protein/creatinine
ratio of\0.1 (g/g) for at least 3 months, after correction of
urinary protein levels for urinary creatinine concentrations,
and (2) \5 red blood cells per high-power ﬁeld on
microscopic evaluation of the urinary sediment.
The secondary endpoint was the efﬁcacy of our treatment
in preventing progressive deterioration of IgAN, which was
assessed by evaluation of renal function and immunological
investigations. The eGFR was calculated using the equation
recommended by the Japanese Society of Nephrology:
eGFR = 194 9 sCr
-1.094 9 age
-0.287 (90.739 if female)
[13], and patients were categorized into three stages of
chronic kidney disease (CKD) based on the eGFR values.
The immunological parameters evaluated were the serum
levels of IgA and IgG. When possible, urinary IgE levels
were also measured along with the urinary levels of inter-
leukin-6 (IL-6) using a highly sensitive IL-6 assay.
The presence or absence of adverse events was exam-
ined during the follow-up period by periodic determination
of blood pressure, hematological and biochemical param-
eters, urinalysis, and infection markers.
Statistics
Statistical analysis was conducted by examination of nor-
mality, and the results were compared using the Wilcoxon
rank sum test. The uniformity of process variables was
analyzed by the chi-squared (v
2) test. To test the equality of
the means, repeated-measures ANOVA was employed. The
statistical signiﬁcance level was set at P\0.05 (for a two-
tailed test). The statistical software package SPSS for
Microsoft Windows version 11.0 (SPSS Inc., Chicago, IL)
was used for the analyses. The mean values and standard
deviations were calculated for data representation.
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Table 1 shows the baseline characteristics of the patients
according to CKD stage. The duration of illness (from
detection of urinalysis abnormalities to tonsillectomy)
averaged 5.7 ± 4.8 (0.4–20) years (unknown in 3 cases).
The duration of illness tended to be longer in elderly
patients. The proportion of RAS inhibitor users was 38%.
This percentage rose signiﬁcantly as CKD stage became
higher. No signiﬁcant change in blood pressure was
observed during the treatment, and none of the patients
required the use of additional antihypertensive medication
after the start of the therapy.
The rate of CR for the 42 patients after tonsillectomy
and steroid pulse therapy plus MZR therapy was 33.3%
(n = 14) at 6 months, 69.1% (n = 29) at 1 year, and
76.2% (n = 32) at 2 years. In many patients, improvement
of proteinuria preceded the improvement of hematuria
(Fig. 1). No patients showed relapse of IgAN during the
follow-up period (average of 2.65 ± 1.03 years) after
obtaining CR.
Overall, there were no signiﬁcant changes in the eGFR
during the follow-up period. Analysis by CKD stage
showed that eGFR remained unchanged in patients with
CKD stages 1 and 2, but was signiﬁcantly improved in
patients with CKD stage 3 at 6 months and later after the
start of treatment (Fig. 2).
Table 2 shows the changes in urinary protein excretion
and laboratory values. Compared with the baseline value, a
signiﬁcant decrease in urinary protein excretion was
observed at 6, 12, and 24 months, and a signiﬁcant
decrease in serum creatinine levels was evident at 12 and
24 months.
Compared with the baseline value, a signiﬁcant
decrease in serum IgA levels was observed at 6, 12, and
24 months. While a signiﬁcant decrease in the serum
levels of IgG and IgE was observed at 6 and 12 months,
these parameters returned almost to baseline levels at
24 months. Compared with the baseline value, there was a
signiﬁcant decrease in the urinary levels of IL-6 at 6, 12,
and 24 months.
During the follow-up period, steroid-induced acne
occurred in three patients as an adverse event and required
treatment, although this was transient. Except for pain,
there were no other tonsillectomy-related complications.
None of the patients developed severe immunosuppression
Fig. 1 Tonsillectomy plus steroid pulse ? oral steroid ? mizoribine
therapy protocol: time-course change in rates of CR of IgAN (rates of
remission of proteinuria and hematuria). Therapy was started (0) at
the time of tonsillectomy (inverted triangle); 1 week later, one course
of methylprednisolone pulse therapy (downward arrow) was admin-
istered. Sulfamethoxazole-trimethoprim (SMX-TMP), an antiplatelet
drug, and an anti-ulcer drug were administered. An oral steroid was
then administered at a dose of 30 mg daily for 4 weeks, and then once
every 2 days in combination with MZR at a dose of 150 mg once
daily. MZR was administered for 11 months, and the antiplatelet drug
was administered for 12 months. SMX-TMP and the anti-ulcer drug
were administered for 13 weeks and then discontinued. The dose of
the steroid was gradually reduced until the end of 7 months, and then
discontinued. The rates of CR of IgAN were determined as the rates
of remission of proteinuria and hematuria at 6, 12, and 24 months.
The number of patients was 42. CR complete remission, UP urinary
protein, UOB urine occult blood
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123(CD4 \400%, IgG \600 mg/dl) or other severe adverse
events such as infections, diabetes, aggravated hyperten-
sion, psychiatric symptoms, hyperuricemia, or serious
changes in laboratory values (data not shown).
Discussion
In this observational study, we investigated the long-term
efﬁcacy and safety and steroid-sparing effect of
Table 1 Baseline characteristics of patients according to CKD stage
Characteristic All (n = 42) CKD stage 1 (n = 18) CKD stage 2 (n = 16) CKD stage 3 (n = 8)
Age (years) 30.4 ± 11.9 22.6 ± 4.9 31.9 ± 6.2 45.0 ± 16.8
Gender (M/F) 17/25 6/12 8/8 3/6
Urine OB score 2.60 ± 0.59 2.78 ± 0.43 2.31 ± 0.70 2.75 ± 0.46
Proteinuria (g/g 9 Cre) 0.98 ± 0.98 0.73 ± 0.68 0.72 ± 0.59 2.03 ± 1.49
No. of patients with UP[1.0 g/g 9 Cre 17 (40.5%) 7 (38.9%) 5 (31.3%) 5 (62.5%)
eGFR (ml/min/1.73 m
2) 85.0 ± 27.7 111.6 ± 12.5 75.3 ± 8.6 44.8 ± 8.4
Serum creatinine (mg/dl) 0.83 ± 0.27 0.62 ± 0.09 0.86 ± 0.16 1.24 ± 0.22
Serum IgA (mg/dl) 360.1 ± 134.4 309.1 ± 93.3 371.1 ± 133.5 447.9 ± 172.4
Serum IgE (IU/ml) 439.2 ± 670.9 338.1 ± 331.3 608.7 ± 1000.2 322.8 ± 413.1
Serum IgG (mg/dl) 1207.9 ± 292.4 1330.7 ± 303.8 1136.5 ± 224.9 1093.6 ± 315.5
Urine HS IL-6 (pg/ml) 10.58 ± 17.26 8.76 ± 9.31 13.09 ± 25.47 9.50 ± 9.60
Duration of illness (years) 5.7 ± 4.8 5.6 ± 4.3 5.4 ± 5.1 7.2 ± 5.8
Histological grade
1 0 (0%) 0 0 0
2 22 (52.4%) 13 8 1
3 17 (40.5%) 5 8 4
4 3 (7.1%) 0 0 3
No. of RAS inhibitor users 16 3 5 8
SBP (mmHg) 116.05 ± 12.07 112.11 ± 8.90 115.88 ± 11.79 125.25 ± 15.04
DBP (mmHg) 68.10 ± 10.42 66.00 ± 10.78 67.63 ± 8.86 73.35 ± 11.68
No. of patients (percentage of patients). For continuous variables, mean ± standard deviation
OB occult blood, UP urinary protein, eGFR estimated glomerular ﬁltration rate, HS IL-6 highly sensitive interleukin 6, SBP systolic blood
pressure, DBP diastolic blood pressure
Fig. 2 Time-course changes in
glomerular ﬁltration rate (GFR).
GFR in patients by CKD stages
1( ﬁlled circles), 2 (ﬁlled
triangles), and 3 (ﬁlled
squares); mean values ± SD.
*P\0.05 (compared with
baseline): Wilcoxon’s rank
sum test. The number of
patients in parentheses
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123tonsillectomy-steroid pulse therapy in combination with
MZR in IgAN patients with stage 1–3 CKD. The rate of
CR, assessed by urinalysis, was 69.1% at 12 months,
increasing to 76.2% at 24 months.
In recent years, IgAN patients who undergo palatine
tonsillectomy to treat focal infection of the palatine tonsils
have been given steroid pulse therapy to prevent recurrence
of IgAN (three courses of mPSL therapy and 1 year of oral
steroid therapy). Reported rates of CR for this treatment
vary depending on the deﬁnition used. Hotta et al. [5]
reported that urinary abnormalities disappeared in 48% of
the patients receiving this treatment and that no patients
showed progressive deterioration. Komatsu et al. [6]
compared tonsillectomy plus steroid pulse therapy (one
course of steroid pulse therapy and 18 months of oral
steroid therapy) with steroid pulse monotherapy, and found
that the former treatment was signiﬁcantly more effective
than the latter, with a CR rate of 61.8% at 24 months. At
the baseline, 37.1% of patients in that study had a urinary
protein excretion of more than 1000 mg, and 8.6% had a
serum creatinine level exceeding 1.2 mg/dl. The patient
baseline characteristics and the histological severity of the
disease in that study were markedly similar to those in our
study. Their ﬁndings reliably reﬂect the prognosis of IgAN
and are useful for comparative assessment of clinical
efﬁcacy.
Since a control group without MZR was not included in
our present study, no deﬁnitive conclusions could be drawn
regarding the efﬁcacy of MZR. However, the present
treatment protocol did show a higher rate of CR at
12 months than the rates reported in previous studies, as
well as continued efﬁcacy for at least 24 months, even
though the total dose of steroids we employed was con-
siderably reduced and the duration of steroid therapy with
additional use of MZR was also very short as compared
with the current therapy without MZR.
None of the patients showed deterioration of renal
function during the 24-month study period, and in fact
patients with CKD stage 3 showed signiﬁcant improvement
of renal function. Since such good outcomes have not been
reported for the current tonsillectomy-steroid pulse
therapy, the improved efﬁcacy was probably attributable to
our additional use of MZR.
MZR is a selective inhibitor of inosine monophosphate
(IMP) dehydrogenase, a rate-limiting enzyme in the de
novo synthetic pathway of guanosine monophosphate
(GMP). MZR selectively inhibits the proliferation of
lymphocytes.
In addition to being a selective inhibitor of lymphocyte
proliferation, MZR has been demonstrated to have some
unique pharmacological properties. The 14-3-3 protein and
heat shock protein 60 (HSP60) are known to be expressed
in the glomeruli of patients with IgAN. It has reported that
MZR binds to the 14-3-3 protein [14] and HSP60 [15].
MZR enhances the transcriptional activity of the gluco-
corticoid receptor via binding to the 14-3-3 protein, sug-
gesting that MZR might enhance the efﬁcacy of steroids
and contribute to steroid sparing [14].
The recovery of renal function in patients with renal
hypofunction is also a relevant issue. It has been shown that
MZR suppresses the inﬁltration of macrophages into the
renal interstitium and the expression of a-smooth muscle
actin (a-SMA) in myoﬁbroblasts [16]. In addition, MZR
dose-dependently ameliorates renal tubulointerstitial
ﬁbrosis in rats with unilateral ureteral obstruction and
signiﬁcantly reduces the generation of osteopontin [10].
In IgAN patients who have received MZR treatment, a
reduction in the number of CD68
? and a-SMA
? cells has
also been reported [11]. Therefore, although we were
unable to clarify the mechanism responsible for the effects
of MZR on renal function, MZR appeared to contribute to
renal recovery mainly by suppressing the inﬁltration of
macrophages into the renal interstitium and the subsequent
reduction of CD68
? and a-SMA
? cells.
IL-6 is produced by human mesangial and tubule cells,
and its urinary levels have been shown to be correlated
with the degree of mesangial proliferation in IgAN [17].
In the present study, a decrease in the urinary IL-6 level
was observed in parallel with the response to therapy.
Since it is difﬁcult to arrive at any deﬁnitive conclusions
about whether the observed beneﬁcial effects of the treat-
ment were due to tonsillectomy or added MZR, a
Table 2 Time course changes in urinary protein excretion and laboratory values
Baseline 6 months 1 year 2 years
Urinary protein (g/g Cr) 0.98 ± 0.98 0.24 ± 0.62*** 0.12 ± 0.51*** 0.09 ± 0.22***
Serum creatinine (mg/dl) 0.83 ± 0.27 0.80 ± 0.22 0.77 ± 0.19** 0.76 ± 0.19**
IgA (mg/dl) 360.1 ± 134.4 283.3 ± 90.9*** 230.0 ± 97.2*** 257.2 ± 122.2***
IgG (mg/dl) 1207.9 ± 292.4 799.0 ± 200.7*** 1008.3 ± 253.2*** 1064.1 ± 205.9
IgE (IU/ml) 439.2 ± 670.9 299.9 ± 372.2* 122.3 ± 130.3*** 374.4 ± 450.6
HS IL-6 (pg/ml) 10.6 ± 17.3 6.1 ± 7.4** 3.0 ± 5.1*** 4.4 ± 7.1**
Wilcoxon’s rank sum test; *P\0.05, **P\0.01, ***P\0.001
HS IL-6 highly sensitive interleukin 6
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tonsillectomy–steroid pulse therapy with and without
MZR.
Although three patients developed adverse events during
the follow-up period, all of these were mild. We consider
that the safety of our therapeutic protocol is attributable to
a lower incidence of adverse events related to MZR than to
other immunosuppressive drugs. When MZR was used in
combination with tonsillectomy, only one course of mPSL
pulse therapy was sufﬁcient, and the total dose of steroids
administered was approximately half that used in the study
by Hotta et al. Administration of MZR is considered to
have reduced the incidence of adverse events that are
typically associated with long-term steroid therapy. We
plan to conduct further studies to assess the long-term
outcomes of our therapeutic protocol.
In conclusion, tonsillectomy-steroid pulse therapy in
combination with MZR appears to be safer than the current
tonsillectomy-steroid pulse therapy alone for treatment of
IgAN, and combination therapy with MZR holds promise
for producing higher rates of CR. Our combination thera-
peutic protocol allows a reduction in the total dose of
steroids, and is also recommended for patients with mild to
moderate renal dysfunction.
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